Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 317

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 317
---
 Company’s equity-based awards recognized for the years ended December 31, 2022, 2023 and
2024, was comprised as follows:

                                              Year ended December 31,                                                       
                                              2022                                    2023                 2024             
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Research and development                    $                            4,289      $         5,073      $         6,454  
  Marketing expenses                                                         210                  474                  753  
  General and administrative                                               2,249                2,379                2,709  
  Total share-based compensation expense      $                            6,748      $         7,926      $         9,916  

As of December 31, 2024, there were
unrecognized compensation costs of $12,114, which are expected to be recognized over a weighted average period of approximately1.82years.

  Warrants to investors:  

  (i)      In July 2019, as part of the investment round of HekaBio K. K, the investors received 651,067 Warrants                                       
           to Ordinary shares with an exercise price of $ 5.04 to be exercise within 4 years from grant date. During the year ended December 31, 2022,  
           all 651,067 Warrants were exercised into 308,540 ordinary shares of the Company.                                                             
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (ii)      Upon completion of the Merger, the 3,880,777 warrants convertible into Preferred A Shares of the Company                                 

During the year
ended December 31, 2022, and 2023 a total of1,556,817and9,984of such warrants were exercised into1,160,016and324ordinary shares
of the Company, respectively.

As of December
31, 2023, a total of2,313,976such warrants were outstanding. On September 16, 2024, these warrants expired unexercised.

  (iii)      During the year ended December 31, 2022, a total of 144,423 Public Warrants were exercised into 144,423 ordinary shares of the Company.  

  Warrants to consultants:  

In April 2016,67,897Warrants to Ordinary